Treatment for radiation-induced pulmonary late effects: Spoiled for choice or looking in the wrong direction?

Current Drug Targets

Volumn 11, Issue 11, 2010, Pages 1386-1394

  Williams, Jacqueline P ^a   Johnston, Carl J ^a   Finkelstein, Jacob N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Lung; Pneumonitis; Pulmonary fibrosis; Radiation

Indexed keywords

AMIFOSTINE; CELECOXIB; DEXAMETHASONE; FREE RADICAL; GENISTEIN; GLUCOCORTICOID; GROWTH FACTOR; INDOMETACIN; MEVINOLIN; N(G) NITROARGININE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHOSPHOROTHIOIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SURFACTANT ASSOCIATED PROTEIN; RADIOPROTECTIVE AGENT;

ARTICLE; CELL DEATH; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LUNG FIBROSIS; LUNG INJURY; LUNG PARENCHYMA; NONHUMAN; QUALITY OF LIFE; RADIATION INJURY; RADIATION PNEUMONIA; THORAX CANCER; XEROSTOMIA; ANIMAL; LUNG; RADIATION EXPOSURE; RADIOTHERAPY; REVIEW;

ANIMALS; HUMANS; LUNG; PULMONARY FIBROSIS; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 79954997865     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011386     Document Type: Article

References (150)

1. Notter RH, Finkelstein JN, Holm BA. Lung Injury: Mechanisms, Pathophysiology, and Therapy. New York: Taylor & Francis, 2005.
2. Penney DP, Rubin P. Specific early fine structural changes in the lung irradiation. Int J Radiat Oncol Biol Phys 1977; 2: 1123-32.
3. Fajardo LF, Berthrong M, Anderson RE. Radiation Pathology. New York: Oxford University Press 2001.
4. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 2007; 25: 3991-4007.
5. Oya N, Sasai K, Tachiiri S, et al. Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis. Int J Hematol 2006; 83: 86-91.
6. Gopal R, Ha CS, Tucker SL, et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001; 92: 1949-58.
7. Carruthers SA, Wallington MM. Total body irradiation and pneumonitis risk: a review of outcomes. Br J Cancer 2004; 90: 2080-4.
8. Vlasov PA, Kvacheva IE. The pathomorphology of the pulmonary infectious complications in acute radiation sickness (based on the autopsy data from persons who died as a result of the accident at the Chernobyl Atomic Electric Power Station. Terapevticheskii Arkhiv 1996; 68: 23-6.
9. Endo A, Yamaguchi Y. Analysis of dose distribution for heavily exposed workers in the first criticality accident in Japan. Radiat Res 2003; 159: 535-42.
10. Siemann DW, Hill RP, Penney DP. Early and late pulmonary toxicity in mice evaluated 180 and 420 days following localized lung irradiation. Radiat Res 1982; 89: 396-407.
11. Trott KD, Herrmann T, Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys 2004; 58: 463-9.
12. Hopewell JW, Rezvani M, Moustafa HF. The pig as a model for the study of radiation effects on the lung. Int J Radiat Biol 2000; 76: 447-52.
13. Desjardins AV. The reaction of the pleura and lungs to roentgen rays. Am J Roentgenol 1926; 16: 444-53.
14. Movsas B, Raffin TA, Epstein AH, Link CJ Jr. Pulmonary radiation injury. Chest 1997; 111: 1061-76.
15. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001; 13: 242-8.
16. Williams JP, Brown SL, Georges GE, et al. Animal models for medical countermeasures to radiation exposure: A CMCR workshop report. Radiat Res 2010; 173: 557-8.
17. Mehta V. Radiation pneumonitis and pulmonary fibrosis in nonsmall-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005; 63: 5-24.
18. Libshitz HI. Radiation changes in the lung. Semin Roentgenol 1993; 28: 303-20.
19. Fan M, Marks LB, Lind P, et al. Relating radiation-induced regional lung injury to changes in pulmonary function tests. Int J Radiat Oncol Biol Phys 2001; 51: 311-7.
20. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001; 50: 899-908.
21. van Rongen E, Tan C, Zurcher C. Early and late effects of fractionated irradiation of the thorax of WAG/Rij rats. Br J Cancer 1986; 7 (suppl): 333-5.
22. Roach M, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995; 13: 2606-12.
23. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol 1996; 14: 1055-64.
24. Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93: 1806-11.
25. Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003; 67: 275-83.
26. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001; 49: 649-55.
27. Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 2006; 66: 1281-93.
28. Kong FM, Ten Haken R, Eisbruch A, Lawrence TS. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005; 32 (2 Suppl 3): S42-54.
29. McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995; 31: 1187-203.
30. th ed. Philadelphia: Lippincott Williams & Wilkins 2006.
31. Chiang CS, Liu WC, Jung SM, et al. Compartmental responses after thoracic irradiation of mice: strain differences. Int J Radiat Oncol Biol Phys 2005; 62: 862-71.
32. Robbins ME, Diz DI. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006; 64: 6-12.
33. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977; 86: 81-92.
34. White DC. An Atlas of Radiation Histopathology. Oak Ridge: U.S. Energy Research & Development Administration 1975.
35. Wang Z, Holm BA, Matalon S, Notter RH. In: Lung Injury. Mechanisms, Pathophysiology, and Therapy. Notter RH, Finkelstein JN, Holm BA, Eds. Boca Raton: Taylor & Francis Group 2005; pp. 297-352.
36. Lemay AM, Haston CK. Radiation-induced lung response of AcB/BcA recombinant congenic mice. Radiat Res 2008; 170: 299-306.
37. Cummings RJ, Mitra S, Foster TH, Lord EM. Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res 2009; 171: 687-97.
38. Kasper M, Fehrenbach H. Immunohistochemical evidence for the occurrence of similar epithelial phenotypes during lung development and radiation-induced fibrogenesis. Int J Radiat Biol 2000; 76: 493-501.
39. Antonadou D, Petridis A, Synodinou M, et al. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 2003; 30: 2-9.
40. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006; 64: 784-91.
41. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 2005; 23: 2145-54.
42. Travis EL, Newman RA, Helbing SJ. WR 2721 modification of type II cell and endothelial cell function in mouse lung after single doses of radiation. Int J Radiat Oncol Biol Phys 1987; 13: 1355-9.
43. Vujaskovic Z, Feng QF, Rabbani ZN, Samulski TV, Anscher MS, Brizel DM. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 2002; 28: 577-90.
44. Levi M, Knol JA, Ensminger WD, et al. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. Drug Metab Dispos 2002; 30: 1425-30.
45. Davis IC, Lang JD, Matalon S. In: Lung Injury. Mechanisms, Pathophysiology and Therapy. Notter RH, Finkelstein JN, Holm BA, Eds. Boca Raton: Taylor & Francis Group 2005; pp. 227-68.
46. Khan MA, Van Dyk J, Yeung IW, Hill RP. Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol 2003; 66: 95-102.
47. Rube CE, Wilfert F, Palm J, et al. Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. Strahlenther Onkol 2004; 180: 442-8.
48. Travis EL. Organizational response of normal tissues to irradiation. Semin Radiat Oncol 2001; 11: 184-96.
49. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995; 33: 99-109.
50. McBride WH, Chiang C-S, Olson JL, et al. A sense of danger from radiation. Radiat Res 2004; 162: 1-19.
51. Abushamaa AM, Sporn TA, Folz RJ. Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 2002; 283: L336-45.
52. Calveley VL, Khan MA, Yeung IW, Van Dyk J, Hill RP. Partial volume rat lung irradiation: temporal fluctuations of in-field and out-of-field DNA damage and inflammatory cytokines following irradiation. Int J Radiat Biol 2005; 81: 887-99.
53. Greenberger JS, Epperly MW. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo 2007; 21: 141-6.
54. Park EM, Ramnath N, Yang GY, et al. High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radic Biol Med 2007; 42: 280-7.
55. Epperly MW, Travis EL, Sikora C, Greenberger JS. Manganese superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: modulation of irradiation-induced mRNA for IL-I, TNF-alpha, and TGF-beta correlates with delay of organizing alveolitis/fibrosis. Biol Blood Marrow Transplant 1999; 5: 204-14.
56. Epperly MW, Epstein CJ, Travis EL, Greenberger JS. Decreased pulmonary radiation resistance of manganese superoxide dismutase (MnSOD)-deficient mice is corrected by human manganese superoxide dismutase-Plasmid/Liposome (SOD2-PL) intratracheal gene therapy. Radiat Res 2000; 154: 365-74.
57. Zhang X, Epperly MW, Kay MA, et al. Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther 2008; 19: 820-26.
58. Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Batinic-Haberle I, Vujaskovic J. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med 2008; 44: 982-9.
59. Browne SE, Roberts II LJ, Dennery PA, et al. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxiatelangiectasia mice. Free Radic Biol Med 2004; 36: 938-42.
60. Melov S, Wolf N, Strozyk D, Doctrow S, Bush AI. Mice transgenic for Alzheimer disease ß-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radic Biol Med 2005; 38: 258-61.
61. Langan AR, Khan MA, Yeung IW, Van Dyk J, Hill RP. Partial volume rat lung irradiation: the protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic. Radiother Oncol 2006; 79: 231-8.
62. Kang JL, Lee HW, Lee HS, et al. Genistein prevents nuclear factor-kappa B activation and acute lung injury induced by lipopolysaccharide. Am J Respir Crit Care Med 2001; 164: 2206-12.
63. Day RM, Barshishat-Kupper M, Mog SR, et al. Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. J Radiat Res 2008; 49: 361-72.
64. Calveley VL, Jelveh S, Langan AR, et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat Res 2010; 173: 602-11.
65. Cohen EP, Fish BL, Irving AA, Rajapurkar MM, Shah SV, Moulder JE. Radiation nephropathy is not mitigated by antagonists of oxidative stress. Radiat Res 2009; 172: 260-4.
66. Johnston CJ, Hernady E, Reed C, Thurston SW, Finkelstein JN, Williams JP. Early alterations in cytokine expression in adult versus developing lung in mice following radiation exposure. Radiat Res 2010; 173: 522-35.
67. White MK, Baireddy V, Strayer DS. Natural protection from apoptosis by surfactant protein A in type II pneumocytes. Exp Cell Res 2001; 263: 183-92.
68. Weber H, Heilmann P, Meyer B, Maier KL. Effect of canine surfactant protein (SP-A) on the respiratory burst of phagocytic cells. FEBS Lett 1990; 270: 90-4.
69. White MK, Strayer DS. Survival signaling in type II pneumocytes activated by surfactant protein-A. Exp Cell Res 2002; 280: 270-9.
70. Sharplin J, Franko AJ. A quantitative histological study of straindependent differences in the effects of irradiation on mouse lung during the early phase. Radiat Res 1989; 119: 1-14.
71. Haston CK, Begin M, Dorion G, Cory SM. Distinct loci influence radiation-induced alveolitis from fibrosing alveolitis in the mouse. Cancer Res 2007; 67: 10796-803.
72. Theuws JC, Muller SH, Seppenwoolde Y, et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. J Clin Oncol 1999; 17: 3091-100.
73. Thomas O, Mahe M, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001; 49: 125-31.
74. Franko AJ, Sharplin J, Ghahary A, Barcellos-Hoff MH. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "nonfibrosing" mice during the latent period and early phase after irradiation. Radiat Res 1997; 147: 245-56.
75. Michalowski AS. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. Acta Oncol 1994; 33: 139-57.
76. Magana E, Crowell RE. Radiation pneumonitis successfully treated with inhaled corticosteroids. Southern Med J 2003; 96: 521-4.
77. Sekine I, Sumi M, Ito Y, et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol 2006; 80: 93-7.
78. Molls A, van Beuningen D, Streffer C, Trott KD. In: Radiopathology of organs and tissues. Scherer E, Streffer C, Trott KD, Eds. Heidelberg: Springer-Verlag 1991.
79. Molls M, Herrmann T, Steinberg F, Feldmann HJ. Radiopathology of the lung: experimental and clinical observations. Recent Res Cancer Res 1993; 130: 109-21.
80. Kosaka Y, Mitsumori M, Araki N, et al. Avascular necrosis of bilateral femoral head as a result of long-term steroid administration for radiation pneumonitis after tangential irradiation of the breast. Int J Clin Oncol 2006; 11: 482-6.
81. Kwok E, Chan CK. Corticosteroids and azathioprine do not prevent radiation-induced lung injury. Can Respir J 1998; 5: 211-4.
82. Gore E. Celecoxib and radiation therapy in non-small-cell lung cancer. Oncology (Williston Park) 2004; 18: 10-14.
83. Belkacemi Y, Rio B, Touboul E. Total body irradiation: techniques, dosimetry, and complications. Cancer Radiother 1999; 3: 162-73.
84. Tochner Z, Barnes M, Mitchell JB, Orr K, Glatstein E, Russo A. Protection by indomethacin against acute radiation esophagitis. Digestion 1990; 47: 81-7.
85. Milas L, Nishiguchi I, Hunter N, et al. Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. Adv Space Res 1992; 12: 265-71.
86. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-9.
87. Mason RP, Walter MF, Day CA, Jacob RF. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 2006; 281: 9337-45.
88. Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006; 98 (Suppl): 34P-41P.
89. Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 2003; 26: 11-14.
90. Johnston CJ, Williams JP, Okunieff P, Finkelstein JN. Radiationinduced pulmonary fibrosis: examination of chemokine and chemokine receptor families. Radiat Res 2002; 157: 256-65.
91. Williams JP, Hernady E, Johnston CJ, et al. Effect of administration of lovastatin on the development of late pulmonary effects following whole lung irradiation in a murine model. Radiat Res 2004; 161: 560-7.
92. Yao HW, Mao LG, Zhu JP. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 2006; 33: 793-7.
93. Sun XF, Wang LL, Wang JK, et al. Effects of simvastatin on lung injury induced by ischaemia-reperfusion of the hind limbs in rats. J Int Med Res 2007; 35: 523-33.
94. Haydont V, Bourgier C, Pocard M, et al. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007; 13(18 Pt 1): 5331-40.
95. Dileto CL, Travis EL, Haston CK, Amos CI, King TM. Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: comparison between a fibrosis-prone and fibrosis-resistant mouse strain Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Radiat Res Can Res 1996; 56: 2596-601.
96. Haston CK, Zhou X, Gumbiner-Russo L, et al. Universal and radiation-specific loci influence murine susceptibility to radiationinduced pulmonary fibrosis. Cancer Res 2002; 62: 3782-8.
97. O'Brien TJ, Letuve S, Haston CK. Radiation-induced strain differences in mouse alveolar inflammatory cell apoptosis. Can J Physiol Pharmacol 2005; 83: 117-22.
98. Osterreicher J, Pejchal J, Skopek J, et al. Role of type II pneumocytes in pathogenesis of radiation pneumonitis: dose response of radiation-induced lung changes in the transient high vascular permeability period. Exp Toxicol Pathol 2004; 56: 181-7.
99. Johnston CJ, Piedboeuf B, Rubin P, Williams J, Baggs R, Finkelstein JN. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res 1996; 145: 762-7.
100. Hong JH, Chiang CS, Tsao CY, Lin PY, McBride WH, Wu CJ. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 1999; 75: 1421-7.
101. Johnston CJ, Wright TW, Rubin P, Finkelstein JN. Alterations in the expression of chemokine mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Exp Lung Res 1998; 24: 321-37.
102. Ts'ao CH, Ward WF, Port CD. Radiation injury in rat lung. I. Prostacyclin (PG12) production, arterial perfusion, and ultrastructure. Radiat Res 1983; 96: 284-93.
103. Moore AH, Olschowka JA, Williams JP, Paige SL, O'Banion MK. Radiation-induced edema is dependent on cyclooxygenase 2 activity in mouse brain. Radiat Res 2004; 161: 153-60.
104. Hallahan DE, Virudachalam S. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation. Proc Natl Acad Sci USA 1997; 94: 6432-7.
105. Hallahan DE, Virudachalam S. Ionizing radiation mediates expression of cell adhesion molecules in distinct histological patterns within the lung. Cancer Res 1997; 57: 2096-9.
106. Finkelstein JN, Johnston C, Barrett T, Oberdörster G. Particulatecell interactions and pulmonary cytokine expression. Environ Health Perspect 1997; 105 (Suppl 5): 1179-82.
107. Sedgwick JB, Menon I, Gern JE, Busse WW. Effects of inflammatory cytokines on the permeability of human lung microvascular endothelial cell monolayers and differential eosinophil transmigration. J Allerg Clin Immunol 2002; 110: 752-6.
108. Porter DW, Ye J, Ma J, et al. Time course of pulmonary response of rats to inhalation of crystalline silica: NF-kappa B activation, inflammation, cytokine production, and damage. Inhal Toxicol 2002; 14: 349-67.
109. Olman MA, White KE, Ware LB, Cross MT, Zhu S, Matthay MA. Microarray analysis indicates that pulmonary edema fluid from patients with acute lung injury mediates inflammation, mitogen gene expression, and fibroblast proliferation through bioactive interleukin-1. Chest 2002; 121 (Suppl 3): 69S-70S.
110. Rube CE, Uthe D, Wilfert F, et al. The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. Int J Radiat Oncol Biol Phys 2005; 61: 1482-92.
111. Xie CH, Zhang MS, Zhou YF, et al. Chinese medicine Angelica sinensis suppresses radiation-induced expression of TNF-alpha and TGF-beta1 in mice. Oncol Reports 2006; 15: 1429-36.
112. Lee KH, Rhee KH. Radioprotective effect of cyclo(Lphenylalanyl-L-prolyl) on irradiated rat lung. J Microbiol Biotechnol 2008; 18: 369-76.
113. Kornman KS. Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am J Clin Nutr 2006; 83: 475S-483S.
114. Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 177-190.
115. Sims J, Towne J, Blumberg H. 11 IL-1 family members in inflammatory skin disease. Ernst Schering Research Foundation Workshop 2006; 56: 187-91.
116. Matsukawa A, Yoshinaga M. Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. Inflamm Res 1998; 47 (Suppl 3): S137-S144.
117. Aikawa N, Fujishima S, Shinozawa Y, Hori S. Cytokine-mediated biological response to severe infections in surgical patients. J Jpn Surg Soc 1996; 97: 1054-9.
118. Pan LH, Ohtani H, Yamauchi K, Nagura H. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996; 46: 91-9.
119. Fan JM, Huang XR, Ng YY, et al. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis 2001; 37: 820-31.
120. Hong JH, Jung SM, Tsao TC, et al. Bronchoalveolar lavage and interstitial cells have different roles in radiation-induced lung injury. Int J Radiat Biol 2003; 79: 159-67.
121. Sime PJ, Gauldie J. In: ARDS in adults. Evans TW, Ed. London: Chapman & Hall Medical 1996; pp. 215-31.
122. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Invest Med 1998; 46: 223-31.
123. Tillie-Leblond I, Pugin J, Marquette CH, et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med 1999; 159: 487-94.
124. Piguet PF. Cytokines involved in pulmonary fibrosis. Int Rev Exp Pathol 1993; 34 Pt B: 173-81.
125. Chen Y, Williams J, Ding I, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002; 12 (1 Suppl 1): 26-33.
126. Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T, Rubin P. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2005; 62: 260-6.
127. Hauff K, Zamzow C, Law WJ, De Melo J, Kennedy K, Los M. Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system. Arch Immunol Ther Exp 2005; 53: 308-20.
128. Lim WK, Fujimoto C, Ursea R, et al. Suppression of immunemediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005; 123: 957-63.
129. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatalonset multisystem inflammatory disease. Arth Rheum 2005; 52: 1283-6.
130. Martin M, LeFaix J-L, Delanian S. TGF-ß1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000; 47: 277-90.
131. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712-9.
132. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009; 27: 3370-8.
133. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque JV. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1378-87.
134. Anscher MS, Thrasher B, Zgonjanin L, et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008; 71: 829-37.
135. Matej R, Housa D, Pouckova P, Zadinova M, Olejar T. Radiationinduced production of PAR-1 and TGF-beta 1 mRNA in lung of C57Bl6 and C3H murine strains and influence of pharmacoprophylaxis by ACE inhibitors. Pathol Res Pract 2007; 203: 107-14.
136. Molteni A, Wolfe LF, Ward WF, et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-ß) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr Pharm Des 2007; 13: 1307-16.
137. Ghosh SN, Zhang R, Fish BL, et al. Renin-angiotensin system suppression mitigates experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys 2009; 75: 1528-36.
138. Jing T, Wang H, Srivenugopal KS, et al. Conditional expression of type 2 angiotensin II receptor in rat vascular smooth muscle cells reveals the interplay of the angiotensin system in matrix metalloproteinase 2 expression and vascular remodeling. Int J Mol Med 2009; 24: 103-10.
139. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-52.
140. Kawano H, Cody RJ, Graf K, et al. Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts. Hypertension 2000; 35: 273-9.
141. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 2007; 27: 2532-9.
142. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediat Inflamm 2009; 752406.
143. Cohen EP, Fish BL, Sharma M, Li XA, Moulder JE. Role of the angiotensin II type-2 receptor in radiation nephropathy. J Lab Clin Med 2007; 150: 106-15.
144. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des 2007; 13: 1317-25.
145. Sharplin J, Franko AJ. A quantitative histological study of straindependent differences in the effects of irradiation on mouse lung during the intermediate and late phases. Radiat Res 1989; 119: 15-31.
146. Travis EL. Genetic susceptibility to late normal tissue injury. Semin Radiat Oncol 2007; 17: 149-55.
147. Sanders CJ, Moore DA 3rd, Williams IR, Gerwirtz AT. Both radioresistant and hemopoietic cells promote innate and adaptive immune responses to flagellin. J Immunol 2008; 180: 7184-92.
148. Janot L, Sirard JC, Secher T, et al. Radioresistant cells expressing TLR5 control the respiratory epithelium's innate immune responses to flagellin. Eur J Immunol 2009; 39: 1587-96.
149. Vijay-Kumar M, Aitken JD, Sanders CJ, et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 2008; 180: 8280-5.
150. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320: 226-30.